This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash | The Motley Fool
Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.

Source: The Motley Fool
Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.